By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Investigators discuss new findings in Biotechnology. According to news originating from Turin, Italy, by NewsRx correspondents, research stated, "Due to the key role played in critical sub-populations, Met is considered a relevant therapeutic target for glioblastoma multiforme and lung cancers. The anti-Met DN30 antibody, engineered to a monovalent Fab (Mv-DN30), proved to be a potent antagonist, inducing physical removal of Met receptor from the cell surface."
Our news journalists obtained a quote from the research from the University of Turin, "In this study, we designed a gene therapy approach, challenging Mv-DN30 in preclinical models of Met-driven human glioblastoma and lung carcinoma. Mv-DN30 was delivered by a Tet-inducible-bidirectional lentiviral vector. Gene therapy solved the limitations dictated by the short half-life of the low molecular weight form of the antibody. In vitro, upon doxycycline induction, the transgene: (1) drove synthesis and secretion of the correctly assembled Mv-DN30; (2) triggered the displacement of Met receptor from the surface of target cancer cells; (3) suppressed the Met-mediated invasive growth phenotype. Induction of transgene expression in cancer cells-transplanted either subcutaneously or orthotopically in nude mice-resulted in inhibition of tumor growth. Direct Mv-DN30 gene transfer in nude mice, intra-tumor or systemic, was followed by a therapeutic response."
According to the news editors, the research concluded: "These results provide proof of concept for a gene transfer immunotherapy strategy by a Fab fragment and encourage clinical studies targeting Met-driven cancers with Mv-DN30."
For more information on this research see: Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. Journal of Molecular Medicine-Jmm, 2014;92(1):65-76. Journal of Molecular Medicine-Jmm can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA (see also Biotechnology).
The news correspondents report that additional information may be obtained from E. Vigna, University of Turin, Dept. of Oncol, Turin, Italy. Additional authors for this research include G. Pacchiana, C. Chiriaco, S. Cignetto, L. Fontani, P. Michieli and P.M. Comoglio.
Keywords for this news article include: Antibodies, Biotechnology, Turin, Italy, Europe, Immunology, Therapeutics, Immunotherapy, Bioengineering, Blood Proteins, Immunoglobulins, Immunomodulation, Cancer Gene Therapy
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC